Point-of-Care: the infectious disease-testing revolution
2025-04-15T10:13:00+10:00
A point of care test is performed at a clinic in Cairns.
Photo: Conor Ashleigh
ʹڲƱ’s Kirby Institute and its collaborators are increasing testing to drive down infectious diseases in Australia.
Treatments for infectious diseases like hepatitis C, sexually transmissible infections and COVID-19 are incredibly effective, but they cannot cure disease among people who are not adequately engaged with the health system.
The Kirby Institute is collaborating with local communities across Australia to offer a more accessible testing option. It is providing diagnostic technologies at the 'point of care', which means test results are made available to patients within hours, enabling treatments to occur the same day, instead of taking weeks or not happening at all.
“To drive down infectious diseases in Australia, we need to ensure all Australians are able to access timely diagnosis and treatment,” says , who leads the Australian Hepatitis C Point-of-Care Testing Program.
“Point-of-care testing is revolutionising the way we test and treat infectious diseases among marginalised populations, such as First Nations Australians, people who inject drugs, and people who are incarcerated. It's essentially bringing clinics and laboratories outside of the hospital and into the places where the people who need to access the service actually are.”
This innovative work is conducted in partnership with , community organisations, and other stakeholders, and last year received further significant funding support from the Australian government.
The funding supports the continuation and expansion of two major national programs of work led by the Kirby Institute: the , led by Prof. Jason Grebely, and the First Nations Molecular Point-Of-Care Testing Program, led by , over two years.
Prof Grebely says that until now, test results could take weeks to be returned to patients, who at that point may no longer be engaged in the health system.
“Using this highly accurate testing technology, we can test for an infection or infections, interpret the results and, if needed, initiate treatment, all within one visit. This is a game-changer when working with marginalised or remotely located population groups. It simplifies the pathway to treatment, and interrupts transmission by getting people onto treatment quicker.”
Australian Hepatitis C Point-of-Care Testing Program
In Australia, there are 74,000 people living with hepatitis C, and most of these people are unaware that they have it. Many people who are at risk of hepatitis C are from marginalised populations groups (such as people who inject drugs and people who are incarcerated). These groups are often neglected by traditional health services.
“Point-of-care testing addresses this because it allows us to bring the lab to the places where people who are at-risk already are, such as drug treatment clinics, needle and syringe programs, community health centres, prisons and community-led organisations,” says Prof Grebely. “The program is designed to scale-up point-of-care hepatitis C testing to get these people onto curative treatment and ultimately eliminate hepatitis C in Australia.
“We're exceptionally pleased the government is investing in this program's life-saving potential.”
In the first phase of the program, nearly 40,000 tests were performed, 3613 were diagnosed with hepatitis C, and 2557 have initiated treatment.
The additional funding will facilitate the expansion of the program to 110 sites across Australia, resulting in approximately 100,000 tests by 2026. These include diverse locations such as drug treatment clinics, prisons, Aboriginal Community Controlled Health Organisations, mobile outreach clinics, homelessness services and mental health facilities.
Infectious disease rates are unacceptably high for many First Nations communities in rural and remote settings due to a range of factors, including isolation from health services. The First Nations Molecular Point-of-Care Testing Program has been designed to address the limited access of First Nations people to testing and treatment through offering point-of-care testing at rural and remote clinics across Australia, including increasing in the number of infectious diseases that can be tested for.
This is a game-changer when working with marginalised or remotely located population groups. It simplifies the pathway to treatment, and interrupts transmission by getting people onto treatment quicker.
Some sites are currently set up to test for SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV), while others are set up to test for chlamydia, gonorrhoea and trichomonas vaginalis. More than half are testing for all seven infections.
“Over the course of the next two years, we plan to expand both the number of sites testing for both and number of tests performed. We are keen to explore new opportunities for community members and primary care staff to be trained in the technology in their own clinics. In addition, in partnership with NACCHO, we are planning to expand the choice of test types to include new priority infections for their populations,” says Prof. Guy.
The program is governed by The First Nations POC Testing Leaders Group, which provides cultural oversight across all operations and works in partnership with peak and individual Aboriginal community-controlled health organisations. Membership of the Leaders Group is comprised of 100% Aboriginal and Torres Strait Islander health service representatives, who are involved in the implementation of POC testing, from all participating jurisdictions.
, Manager of the Yandamanjang First Nations health research at the Kirby Institute, says the program has been transformational for testing priority infectious disease in remote communities.
“There are often huge geographical distances between health services and laboratories, which can mean that when someone does attend a clinic for a test, it can take days or weeks for a result to be returned to the patient and, if needed, treatment provided,” he said. “Point-of-care testing addresses this by offering accessible testing and timely treatment to these who need it. It also positively impacts public health due to reduced onward transmission and a reduction in health complications.”
Demonstrating impact
The STI component of the program, led by , has been running since 2016 and the Respiratory component since 2020, in partnership with health services who have led the implementation.
An NHMRC-funded evaluation found the introduction of point-of-care testing more than doubled the proportion of people treated and cured of an STI within two days. The evaluation also found that STI point-of-care testing was cost-effective and led to modelled reductions in risk of pelvic inflammatory disease, preterm and low-birth-weight babies.
An evaluation of the COVID-19 program, commissioned by the Australian government in 2023, found that the program averted around 122,000 infections that would have likely arisen in the months after the first infection was identified in a remote Aboriginal and/or Torres Strait Islander community, and led to a cost saving of between $337 million and $1.8 billion for the Australian healthcare system.
Related stories
-
ʹڲƱ Kirby Institute’s remote testing program wins major university award
-
$1.5m grant to evaluate hepatitis C elimination in Australia’s prison population
-
A new at-home test will soon be available for chlamydia and gonorrhoea. Here’s what to know
-
Do infectious diseases cause dementia? AI will be looking into it